Relapsed B-cell Non-Hodgkin Lymphoma
Oncology·MeSH: Lymphoma, B-Cell
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| aNK | ImmunityBio, Inc. (IBRX) |
Phase 2(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed B-cell Non-Hodgkin Lymphoma?
BioSniper tracks 2 drugs in development for Relapsed B-cell Non-Hodgkin Lymphoma across 1 company.
How many clinical trials target Relapsed B-cell Non-Hodgkin Lymphoma?
There are 1 clinical trial targeting Relapsed B-cell Non-Hodgkin Lymphoma tracked by BioSniper.
What is the prevalence of Relapsed B-cell Non-Hodgkin Lymphoma?
The estimated prevalence of Relapsed B-cell Non-Hodgkin Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Relapsed B-cell Non-Hodgkin Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis